Insulin Delivery Devices Market: Trends And Developments
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period.
The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The Insulin Delivery Devices Marketis expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period.
Ask for Free PDF Brochure :- Insulin Delivery Devices Market
Key Market Drivers:- 1 Growing Diabetic Population2 Technological Advancements in Insulin Delivery Devices3 Favorable Reimbursement Environment and Government Support in Selected Countries4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices
Market Segmentation:-
Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region.
By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure.
Regional Analysis: -
In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada.
Request for Free Sample Pages:- Insulin Delivery Devices Market
Top Key Players :-
The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.